91ÑÇÉ«´«Ã½

Journal News

Preventing missed diagnoses of hyperekplexia in newborns

Ken Farabaugh
Nov. 3, 2022

People with hyperekplexia react profoundly to sudden noises, movements and touch.

“Loud noises such as clapping your hands can cause an excessive startle in newborns,” explained Ghada Aboheimed, an assistant professor at King Saud University in Saudi Arabia and the lead author of of the condition in the Journal of Biological Chemistry.

In addition to excessive startle response, hyperekplexia is characterized by nonepileptic seizures and extreme muscle stiffness that even can prevent voluntary movement. This rare condition often is diagnosed at birth and is known to be caused by genetic mutations in GLRA1, SLC6A5, GLRB and several other genes that play roles in glycine-mediated signaling in the nervous system.

In , Aboheimed and co-authors discovered in a newborn girl a novel mutation in GLRB that caused a recessive form of hyperekplexia. “We collected samples from hyperekplexia patients and their families from different hospitals in Saudi Arabia and analyzed the genetic cause of their disease using advanced sequencing and analysis technologies,” Aboheimed said.

The mutation that the team identified led to decreased expression of the beta-subunit of the glycine receptor ion channel. Using coimmunoprecipitation and confocal microscopy, the researchers found altered cellular localization of the α/β receptor dimer. Using patch clamp electrophysiology, they demonstrated reduced glycine sensitivity of the mutant receptor. The mutated residue, found on an outer transmembrane helix, introduced steric clashes that destabilized the protein and led to decreased activation of the ion channel upon glycine binding.

Aboheimed said that she hopes the identification of this and similar mutations can help doctors accurately diagnose hyperekplexia in newborns.

“When added to the epilepsy gene screening panels, (the genes) will help to avoid misdiagnosing hyperekplexia with epilepsy, resulting in early genetic diagnosis of the disease and preventing the use of multiple antiepileptic treatments administered to newborns, and potentially death due to apnea,” she said.

People with hyperekplexia usually are treated with the drug clonazepam, which is an anti-anxiety and anti-spastic medication. The girl in Aboheimed’s study found to have the novel mutation in GLRB responded well to clonazepam and is in school, she said. As they get older, most patients experience sudden falls, which can cause serious injuries, and excessive startle to sudden loud noises, which can prevent them from doing normal activities such as driving a car.

“Studying rare diseases such as hyperekplexia can help patients’ families understand the genetic cause of the disease and the inheritance mode … But working on such cases sometimes leads to identifying novel genes and thus further understanding the pathogenesis of the disease,” Aboheimed said. “Our next step is to identify other possible genes related to this disease to help us broaden our understanding of its pathology, and eventually to develop personalized treatment using gene therapy.”

Enjoy reading 91ÑÇÉ«´«Ã½ Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ken Farabaugh

Ken Farabaugh is a former 91ÑÇÉ«´«Ã½ science editor.

Get the latest from 91ÑÇÉ«´«Ã½ Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Unraveling oncogenesis: What makes cancer tick?
91ÑÇÉ«´«Ã½ Annual Meeting

Unraveling oncogenesis: What makes cancer tick?

April 7, 2025

Learn about the 91ÑÇÉ«´«Ã½ 2025 symposium on oncogenic hubs: chromatin regulatory and transcriptional complexes in cancer.

Exploring lipid metabolism: A journey through time and innovation
91ÑÇÉ«´«Ã½ Annual Meeting

Exploring lipid metabolism: A journey through time and innovation

April 4, 2025

Recent lipid metabolism research has unveiled critical insights into lipid–protein interactions, offering potential therapeutic targets for metabolic and neurodegenerative diseases. Check out the latest in lipid science at the 91ÑÇÉ«´«Ã½ annual meeting.

Melissa Moore to speak at 91ÑÇÉ«´«Ã½ 2025
91ÑÇÉ«´«Ã½ Annual Meeting

Melissa Moore to speak at 91ÑÇÉ«´«Ã½ 2025

April 2, 2025

Richard Silverman and Melissa Moore are the featured speakers at the 91ÑÇÉ«´«Ã½ annual meeting to be held April 12-15 in Chicago.

 A new kind of stem cell is revolutionizing regenerative medicine
Feature

A new kind of stem cell is revolutionizing regenerative medicine

April 1, 2025

Induced pluripotent stem cells are paving the way for personalized treatments to diabetes, vision loss and more. However, scientists still face hurdles such as strict regulations, scalability, cell longevity and immune rejection.

Engineering the future with synthetic biology
91ÑÇÉ«´«Ã½ Annual Meeting

Engineering the future with synthetic biology

March 31, 2025

Learn about the 91ÑÇÉ«´«Ã½ 2025 symposium on synthetic biology, featuring applications to better human and environmental health.

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance
Webinar

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance

March 28, 2025

Alejandro Vila, an 91ÑÇÉ«´«Ã½ Breakthroughs speaker, discussed his work on metallo-β-lactamase enzymes and their dependence on zinc.